Add to Cart View Cart/Checkout More Products

Bio-Identical Hormone Replacement Therapy CD

Permanent storage and easy retrieval of Journal articles and formulations.
Only $95 per CD.

Bio-Identical Hormone Replacement Therapy CD
  • Print Journal articles in color from the pdf file for your marketing needs.
  • Eliminate long searches through past issues for articles and formulations.
This CD contains the following articles listed by volume, issue and page number:

CANCER AND AIDS RELATED ARTICLES
TitleVolume/IssuePage
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 2 Vol. 17 No. 6 446
Metyrosine 250-mg Capsules Vol. 17 No. 6 506
Disguising the Taste of Antiretrovirals for Pediatric Patients Infected with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Creative Flavor Compounding and Techniques, Part 1 Vol. 17 No. 5 388
Fluorouracil 50-mg/mL Injection Vol. 17 No. 5 417
Mesna 100-mg/mL Injection Vol. 17 No. 5 420
Methotrexate 25-mg/mL Injection Vol. 17 No. 5 421
Dacarbazine 200-mg/mL Injection Vol. 17 No. 4 330
Mercaptopurine 75-mg Capsules Vol. 17 No. 3 234
PostScription: The Pharmacist's Role in the Treatment of Cancer: A Personal Plea and Testimonial Vol. 17 No. 3 262
Dexrazoxane 1-mg/mL Injection Vol. 17 No. 2 149
Paclitaxel 6-mg/mL Injection Vol. 17 No. 2 151
Thiotepa 15-mg/mL Injection Vol. 17 No. 2 152
Granisetron 1-mg/mL Injection Vol. 17 No. 1 66
Octreotide 50-mcg/mL Injection Vol. 17 No. 1 72
Testosterone Cypionate 100-mg/mL Injection Vol. 17 No. 1 73
Calculations Vol. 16 No. 6 498
Use of a Closed-system Drug Transfer Device (PhaSeal) and Impact on Preparation Time Vol. 16 No. 5 431
Compounding of Slow-release Niacinamide Capsules: Feasibility and Characterization Vol. 16 No. 5 434
Ondansetron Hydrochloride 2-mg/mL Injection Vol. 16 No. 4 339
Gastrointestinal Mucositis: Focus on the Treatment of the Effects of Chemotherapy and Radiotherapy on the Rectum Vol. 16 No. 2 117
Stability of Carboplatin, Paclitaxel, and Docetaxel with Acetyl-L-carnitine During Simulated Y-site Administration Vol. 16 No. 1 82
Oral Mucositis: Etiology and Clinical and Pharmaceutical Management Vol. 16 No. 1 22
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers Vol. 15 No. 6 458
Thioguanine 20-mg/mL Oral Suspension Vol. 15 No. 6 506
Morphine 6-mg/mL, Haloperidol 0.5-mg/mL, and Hyoscine 6-mg/mL Infusion Vol. 15 No. 6 504
Physiochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags Vol. 15 No. 6 515
Granisetron Hydrochloride 0.2-mg/mL Oral Suspension Vol. 15 No. 5 419
Study of Microbiological Safety of 25 Oncology Drugs After Multiple Uses in Aseptic Conditions Vol. 15 No. 5 428
Methylprednisolone 4-mg/mL Oral Suspension Vol. 15 No. 4 340
Panitumumab 2.5-mg/mL in 0.9% Sodium Chloride Injection Vol. 14 No. 5 428
Potential Treatments for Radiation Dermatitis Vol. 14 No. 3 210
Cyclophosphamide 10-mg/mL Oral Suspension Vol. 14 No. 3 245
Sunitinib 10-mg/mL Oral Suspension Vol. 14 No. 3 248
Hormonal Influences in Prostate Cancer: An Update of a Complex Subject Vol. 14 No. 2 100
Developing a Tretinoin Oral Liquid for Patients Who Cannot Take Capsules Vol. 14 No. 2 118
Mechlorethamine Hydrochloride 0.02% Topical Vol. 13 No. 5 434
Myristyl Nicotinate 5% Topical Gel Vol. 13 No. 5 435
Aprepitant 20-mg/mL Oral Liquid Vol. 13 No. 2 153
Doxorubicin Hydrochloride 1-mg/mL in Sodium Chloride Solution Intravesical Instillation Vol. 13 No. 2 155
Ionic Hydration Solution for Anti-Cancer Therapy Vol. 13 No. 2 156
Compounding for Cancer in Companion Animals Vol. 13 No. 1 42
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration Vol. 12 No. 5 460
Compounding Challenges for Immunocompromised Patients Vol. 12 No. 6 482
Tretinoin and Dexpanthenol Gel Vol. 12 No. 4 361
Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration Vol. 12 No. 4 368
Cancer-Related Terminology: Glossaries for Compounding Pharmacists and Their Clients Vol. 12 No. 1 16
Hospice and Compounding Pharmacy: Once Inseperable Vol. 12 No. 1 28
Calculations: Compounding for Cancer Patients Vol. 12 No. 1 62
Temozolomide 10-mg/mL Oral Liquid Vol. 11 No. 4 336
Levorphanol for Excruciating Pain from Oral Cancer: A Case Report Vol. 11 No. 3 212
Busulfan 2-mg/mL Oral Liquid Vol. 11 No. 2 155
Ondansetron Hydrochloride 0.8mg/mL Oral Liquid Vol. 11 No. 2 158
Phenoxybenzamine Hydrochloride 2-mg/mL Oral Liquid Vol. 11 No. 2 160
Principles of Pediatric Palliative Care and Pain Control Vol. 11 No. 1 10
Physical and Chemical Stability of Palonosetron with Metoclopramide and Promethazine During Simulated Y-Site Administration Vol. 11 No. 1 82
Cyclophosphamide 2-mg/mL Oral Liquid Vol. 10 No. 6 454
Dermatological Effects from Years in the Sun: Compounding Opportunities Vol. 10 No. 5 336
Hydroxyurea 100 mg/mL Vol. 10 No. 5 384
Indinavir 10-mg/mL Oral Liquid Vol. 10 No. 5 385
Temozolomide Stability in Extemporaneously Compounded Oral Suspensions Vol. 10 No. 5 396
Rifabutin 20-mg/mL Oral Liquid Vol. 10 No. 4 305
Granisetron 0.05-mg/mL Oral Suspension Vol. 10 No. 3 222
Mesna 20-mg/mL Syrup Vol. 10 No. 3 224
Physical and Chemical Stability of Palonosetron Hydrochloride with Dacarbazine and with Methylprednisolone Sodium Succinate During Simulated Y-Site Administration Vol. 10 No. 3 234
Chlorambucil 2-mg/mL Oral Liquid Vol. 10 No. 1 59
Efavirenz 20-mg/mL Oral Liquid, Anhydrous Vol. 10 No. 1 62
Mercaptopurine 50-mg/mL Oral Liquid Vol. 10 No. 1 64
Thioguanine 40-mg/mL Oral Liquid Vol. 10 No. 1 68
Dolasetron 10-mg/mL Oral Liquid Vol. 9 No. 6 475
Brompton's Mixture Vol. 9 No. 4 312
Physical and Chemical Stability of Palonosetron Hydrochloride with Fluorouracil and with Gemcitabine Hydrochloride during Simulated Y-site Administration Vol. 9 No. 4 320
Compounding Antiangiogenic Cancer Therapy for Animals Vol. 9 No. 3 195
Piroxicam 2-mg/mL Oral Liquid, Veterinary Vol. 9 No. 3 234
Physical and Chemical Stability of Palonosetron Hydrochloride with Lorazepam and Midazolam Hydrochloride during Simulated Y-Site Administration Vol. 9 No. 3 235
Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration Vol. 9 No. 3 238
Book and Literature Reviews Vol. 8 No. 5 324
Acyclovir 5% and Chlorhexidine Diacetate 0.2% Topical Gel Vol. 8 No. 5 383
Book and Literature Reviews Vol. 8 No. 4 244
Diphenhydramine HCl 0.1%, Lidocaine HCl 1%, Misoprostol 0.0024% and Triamcinolone Acetonide 0.12% Oral Rinse Vol. 8 No. 4 296
Glycopyrrolate 0.5-mg/mL Oral Liquid Vol. 8 No. 3 218
Stomatitis Mouthwash Vol. 8 No. 2 140
Tacrolimus 0.5-mg/mL Oral Liquid Vol. 8 No. 2 141
Stability of Oral Liquid Dosage Forms of Glycopyrrolate Prepared with the Use of Powder Vol. 7 No. 5 386
ABHR in PLO (Lorazepam, Diphenhydramine HCl, Haloperidol, Metoclopramide HCl) Vol. 7 No. 3 183
The Hormonal Link to Breast Cancer: The Estrogen Matrix Vol. 6 No. 4 250
Sterilization of Talc for Use in Pleurodesis Vol. 6 No. 2 140
Antineoplastic Agents Vol. 5 No. 4 268
A New High-Performance Liquid Chromatographic Method for Fludarabine and Fludarabine Phosphate Compounded in Liposomes Vol. 5 No. 4 320
Mitomycin 0.02% Ophthalmic Solution Vol. 5 No. 3 209
Promethazine HCl 50-mg/mL in PLO Gel Vol. 5 No. 1 51
Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome Vol. 4 No. 5 334
Hospice and the Role of the Compounding Pharmacist Vol. 4 No. 4 246
Nausea and Vomiting in Hospice Patients Vol. 4 No. 4 250
Ketamine for Pain in Hospice Patients Vol. 4 No. 4 253
Custom-Making Medications for the Hospice Patient Vol. 4 No. 4 255
Surviving Cancer - How the Compounding Pharmacist Can Help Vol. 4 No. 4 257
Providing Positive Outcomes through Compounding for Animal Cancer Patients Vol. 4 No. 4 264
Dacarbazine 8-mg/mL, Doxorubicin HCl 0.8-mg/mL and Ondansetron 0.64-mg/mL injection Vol. 4 No. 4 296
Dexamethasone 1.2%, Lorazepam 0.1%, Haloperidol 0.1%, Diphenhydramine HCl 2.4% and Metoclopramide HCl 2.4% in PLO Vol. 4 No. 4 297
Doxorubicin HCl 0.4-mg/mL, Ondansetron HCl 0.48-mg/mL and Vincristine Sulfate 14-mcg/mL Injection Vol. 4 No. 4 298
Misoprostol 0.0024% Mouth Rinse for Oral Ulcerations Vol. 4 No. 4 302
Ondansetron HCl 8-mg/mL in PLO Vol. 4 No. 4 305
Stability of 5-Fluorouracil in an Extemporaneously Compounded Ophthalmic Solution Vol. 4 No. 4 320
Tamoxifen Citrate - A Potential Therapy for the Treatment of Keloids Vol. 3 No. 5 380
Tamoxifen Citrate Cream 0.1% Vol. 3 No. 5 381
Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration Vol. 3 No. 3 241
Oral Ulceration Mouthwash Vol. 3 No. 1 10
Five-Day Stability of Vinorelbine in 5% Dextrose Injection and in 0.9% Sodium Chloride Injection at Room Temperature Vol. 3 No. 1 67
Minimizing the Risk of Teratogenic Substance Exposure for Pregnant Compounding Pharmacists Vol. 2 No. 6 414
Compatibility of Paclitaxel Injection Diluent with Two Reduced-Phthalate Administration Sets for the Acclaim Pump Vol. 2 No. 5 382
Fluorouracil 5% Topical Stick Vol. 2 No. 4 300
Paclitaxel Compatibility with IV Express Filter Unit Vol. 2 No. 3 243
Estrogen and Breast Cancer: Is There a Link? Vol. 2 No. 1 21
Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux through Rabbit Rectal Membrane Vol. 2 No. 1 83
Stability of Mechlorethamine Hydrochloride 0.01% Ointment in Aquaphor® Base Vol. 2 No. 1 89
Compounding Pharmacists Play a Vital Role in AIDS Treatment Vol. 1 No. 6 386
Doxorubicin HCl-Vincristine Sulfate Injection Vol. 1 No. 5 324
Granisetron HCl-Dexamethasone Sodium Phosphate Injection Vol. 1 No. 5 326
Metoclopramide-Lorazepam-Mannitol-Prochlorperazine Antiemetic Injection Vol. 1 No. 5 328
Ondansetron HCl-Dexamethasone Sodium Phosphate Injection Vol. 1 No. 5 332
Ondansetron HCl-Doxorubicin HCl-Dacarbazine Injection Vol. 1 No. 5 333
Ondansetron HCl-Doxorubicin Sulfate-Vincristine Sulfate Injection (2 concentrations) Vol. 1 No. 5 334
Stability of Mitomycin Aqueous Solution When Stored in Tuberculin Syringes Vol. 1 No. 4 282
Antiemetic Injection for Cancer Chemotherapy Vol. 1 No. 3 175
Rectal and Stomal Administration of Analgesic Suppositories Vol. 1 No. 1 12
Aromatherapy and the Hospice Patient Vol. 1 No. 1 18
ABH Hard Troche Vol. 1 No. 1 26
ABH Soft Troche Vol. 1 No. 1 27
ABH Sugar Troche Vol. 1 No. 1 27
Antiemetic Suppositories of the Gralla Type Vol. 1 No. 1 28
Metoclophen Nausea Suppositories Vol. 1 No. 1 31
Metoclophen-Modified Nausea Suppositories Vol. 1 No. 1 31
Ondansetron HCl Suppositories Vol. 1 No. 1 34
Scopolamine Hydrobromide 0.4-mg/0.1-mL Nasal Solution Vol. 1 No. 1 37
Scopolamine Hydrobromide 0.25-mg/0.1-mL Topical Gel Vol. 1 No. 1 38
Compounding an Extended Stability Admixture of Paclitaxel for Long-Term Infusion Vol. 1 No. 1 49

HOSPICE/PALLIATIVE CARE RELATED ARTICLES
TitleVolume/IssuePage
Palliative Care and Compounding for Household Pets Vol. 16 No. 6 452
Compounded Oral Ketamine for Severe Depression, Anxiety, and Pain in a Hospice Patient with End-stage Chronic Obstructive Pulmonary Disease, Cardiopulmonary Failure, and Severe Renal Insufficiency: A Case Report Vol. 16 No. 5 364
When Traditional Medicine Fails Vol. 14 No. 1 6
Compounding for Cancer in Companion Animals Vol. 13 No. 1 42
Topical Treatment of Neuropathic Pain Vol. 12 No. 3 182
Hospice and Compounding Pharmacy: Once Inseperable Vol. 12 No. 1 28
Principles of Pediatric Palliative Care and Pain Control Vol. 11 No. 1 10
Hospice Symptom Relief Kit: An Update Vol. 10 No. 4 288
Aseptic Compounding in New Zealand and the Use of Still Air Boxes Vol. 10 No. 4 293
Initial Selection of Antiemetics in End-of-Life Care: A Retrospective Analysis Vol. 10 No. 2 147
Hospice from a Compounding Pharmacist's Perspective Vol. 10 No. 2 89
ABHR Gel in the Treatment of Nausea and Vomiting in the Hospice Patient Vol. 10 No. 2 95
The Story of Hospice Vol. 10 No. 2 100
The Dying Process Vol. 10 No. 2 103
Current Topical Treatments in Wound Healing - Part 1 Vol. 8 No. 4 269
Scopolamine Hydrobromide 0.25-mg/0.1-mL Topical Gel Vol. 8 No. 3 185
Indomethacin 50-mg Suppositories Vol. 7 No. 5 375
ABHR in PLO (Lorazepam, Diphenhydramine HCl, Haloperidol, Metoclopramide HCl) Vol. 7 No. 3 183
Hospice and the Role of the Compounding Pharmacist Vol. 4 No. 4 246
Nausea and Vomiting in Hospice Patients Vol. 4 No. 4 250
Ketamine for Pain in Hospice Patients Vol. 4 No. 4 253
Custom-Making Medications for the Hospice Patient Vol. 4 No. 4 255
Basics of Compounding: Compounding Suppositories: Part I - Theoretical Considerations Vol. 4 No. 4 289
Dexamethasone 1.2%, Lorazepam 0.1%, Haloperidol 0.1%, Diphenhydramine HCl 2.4% and Metoclopramide HCl 2.4% in PLO Vol. 4 No. 4 297
Managing Pain in the Terminally Ill Vol. 2 No. 2 111
The Symptom Relief Kit for Hospice Patients Vol. 2 No. 2 116
Compounding Pharmacists Play a Vital Role in AIDS Treatment Vol. 1 No. 6 386
Hospice Care and the Pharmacist Vol. 1 No. 1 11
Rectal and Stomal Administration of Analgesic Suppositories Vol. 1 No. 1 12
Aromatherapy and the Hospice Patient Vol. 1 No. 1 18
Aromatherapy Mood Elevation No. 1 Vol. 1 No. 1 20
Aromatherapy Mood Elevation No. 2 Vol. 1 No. 1 21
ABH Hard Troche Vol. 1 No. 1 26
ABH Soft Troche Vol. 1 No. 1 27
ABH Sugar Troche Vol. 1 No. 1 27
Morphine Sulfate Slow-Release Suppositories Vol. 1 No. 1 32
Ondansetron HCl Suppositories Vol. 1 No. 1 34
Morphine Suppositories Vol. 1 No. 1 36